MACROD2 expression predicts response to 5-FU-based chemotherapy in stage III colon cancer.

Autor:	van den Broek E; Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands.; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands., den Uil SH; Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands.; Department of Surgery, Spaarne Gasthuis, Haarlem, The Netherlands., Coupé VMH; Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, The Netherlands., Delis-van Diemen PM; Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands.; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Bolijn AS; Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands.; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Bril H; Department of Pathology, Spaarne Gasthuis, Haarlem, The Netherlands., Stockmann HBAC; Department of Surgery, Spaarne Gasthuis, Haarlem, The Netherlands., van Grieken NCT; Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands., Meijer GA; Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands.; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Fijneman RJA; Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands.; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Jazyk:	angličtina
Zdroj:	Oncotarget [Oncotarget] 2018 Jun 29; Vol. 9 (50), pp. 29445-29452. Date of Electronic Publication: 2018 Jun 29 (Print Publication: 2018).
DOI:	10.18632/oncotarget.25655
Abstrakt:	Background: Colorectal cancer (CRC) is caused by genetic aberrations. MACROD2 is commonly involved in somatic focal DNA copy number losses, in more than one-third of CRCs. In this study, we aimed to investigate the association of MACROD2 protein expression with clinical outcome in stage II and stage III colon cancer. Methods: Tissue microarrays (TMA) containing formalin-fixed paraffin-embedded tissue cores from 386 clinically well-annotated primary stage II and III colon cancers were stained by immunohistochemistry and evaluated for MACROD2 protein expression. Disease-free survival (DFS) analysis was performed to estimate association with clinical outcome. Results: Loss of nuclear MACROD2 protein expression in epithelial neoplastic cells of stage III microsatellite stable (MSS) colon cancers was associated with poor DFS within the subgroup of 59 patients who received 5-fluorouracil (5-FU)-based adjuvant chemotherapy (p=0.005; HR=3.8, 95% CI 1.4-10.0). Conclusion: These data indicate that low nuclear expression of MACROD2 is associated with poor prognosis of patients with stage III MSS primary colon cancer who were treated with 5-FU-based adjuvant chemotherapy. Competing Interests: CONFLICTS OF INTEREST None.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu